Discontinued — last reported Q2 '24
Non-Current Assets
AFS Securities
Eli Lilly AFS Securities decreased by 40.9% to $119.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 35.5%, from $185.10M to $119.40M.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ2 2024
Parent metricTotal investment securities
How to read this metric
An increase reflects capital allocation toward investment portfolios, while a decrease may signal portfolio rebalancing or asset liquidation.
Detailed definition
Available-for-sale securities are debt or equity investments that are not classified as trading or held-to-maturity, and...
Peer comparison
Common in the investment portfolios of banks and insurance companies.
Metric ID:
fin_afs_securitiesHistorical Data
14 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $163.90M | $157.80M | $197.70M | $170.40M | $197.80M | $219.40M | $213.20M | $201.60M | $222.40M | $185.70M | $185.10M | $171.00M | $201.90M | $119.40M |
| QoQ Change | — | -3.7% | +25.3% | -13.8% | +16.1% | +10.9% | -2.8% | -5.4% | +10.3% | -16.5% | -0.3% | -7.6% | +18.1% | -40.9% |
| YoY Change | — | — | — | +4.0% | +25.3% | +11.0% | +25.1% | +1.9% | +1.4% | -12.9% | -8.2% | -23.1% | +8.7% | -35.5% |
Range$119.40M – $222.40M
CAGR-9.3%
Avg YoY Growth-0.2%
Median YoY Growth+1.9%
AFS Securities at Other Companies
Frequently Asked Questions
- What is Eli Lilly's afs securities?
- Eli Lilly (LLY) reported afs securities of $119.40M in Q3 2025.
- How has Eli Lilly's afs securities changed year-over-year?
- Eli Lilly's afs securities decreased by 35.5% year-over-year, from $185.10M to $119.40M.
- What does afs securities mean?
- Investments in securities that are held for potential sale and marked to fair market value.